TABLE 3

mRNA levels in 12- and 22-week-old control (lean) and diabetic (ZDF) rats and 12-week-old rats treated with WY14,643 measured by quantitative PCR (n = 3)

12 weeks
22 weeks
Low dose
High dose
LeanZDFLeanZDFLean WY14,643ZDF WY14,643Lean WY14,643ZDF WY14,643
MCAD1 ± 0.160.84 ± 0.121.0 ± 0.131.1 ± 0.120.97 ± 0.340.79 ± 0.042.3 ± 0.50*1.8 ± 0.40*
CPT1a1 ± 0.140.49 ± 0.090.75 ± 0.180.67 ± 0.090.74 ± 0.270.38 ± 0.050.67 ± 0.150.60 ± 0.10
HMGCS21 ± 0.121.0 ± 0.100.82 ± 0.030.92 ± 0.051.0 ± 0.301.5 ± 0.11*1.2 ± 0.20*1.4 ± 0.40
PDK41 ± 0.301.3 ± 0.531.3 ± 0.142.3 ± 0.561.3 ± 0.393.9 ± 1.7*22 ± 2.5*9.8 ± 0.50*
CD36/FAT1 ± 0.205.6 ± 1.1*1.7 ± 0.153.9 ± 0.225.2 ± 1.2*2.2 ± 0.20*9.3 ± 0.81*5.7 ± 0.45
Cyp4a1 ± 0.160.41 ± 0.21*0.95 ± 0.240.37 ± 0.203.7 ± 2.0*1.5 ± 0.31*4.9 ± 0.50*3.2 ± 0.92*
ACOX11 ± 0.150.80 ± 0.060.88 ± 0.71.20 ± 0.044.2 ± 2.3*2.4 ± 0.20*9.5 ± 1.0*8.8 ± 1.5*
PGC-1α1 ± 0.061.0 ± 0.270.66 ± 0.090.85 ± 0.190.55 ± 0.06*0.34 ± 0.06*0.44 ± 0.15*0.42 ± 0.20*
PPAR-α1 ± 0.400.77 ± 0.220.94 ± 0.260.95 ± 0.050.77 ± 0.230.61 ± 0.201.1 ± 0.201.0 ± 0.15
  • Data are means ± SE.

  • *

    * P < 0.05 between treated and untreated groups.

  • P < 0.05 between control and diabetic groups.

  • P < 0.05 between young and old groups. ACOX, acyl-CoA oxidase; HMGCS, hydroxymethylglutaryl-CoA synthase; MCAD, medium-chain acyl-CoA dehydrogenase; PDK, pyruvate dehydrogenase kinase.